Inicio / De Interés / Notigalderma / Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC

Comparison of topical methyl aminolevulinate photodynamic therapy versus placebo photodynamic therapy in nodular BCC

Basal cell carcinoma (BCC) is a frequent skin malignancy, and accounts for approximately 75% of all non-melanoma skin cancers, affecting mostly the head and neck in fair-skinned individuals.

Simple surgical excision is currently regarded as the treatment of choice; however, cosmetic outcome is often less than optimal. Photodynamic therapy (PDT) is a treatment modality, involving the activation of a photosensitizing agent by light, leading to the formation of reactive oxygen species. This process results in local tissue destruction and may, therefore, offer an attractive alternative to surgery. Application of methyl aminolevulinate (MAL) leads to the selective formation of photoactive porphyrins in tumor cells. Previous clinical experience has been promising and patients with nodular BCC (nBCC) were recruited for participation in this multicenter, randomized trial to assess the efficacy, safety and cosmetic outcome of MAL-PDT.

Descargue artículo completo:

comparison-of-topical-mal-pdt-vs-placebo-pdt-in-nbcc.pdf

Acerca de Laboratorios Galderma

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies